P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

January 2008

Features

Impact of Bipolar Disorder on the Family: Utilization and Cost of Health Care Resources

The authors describe a study in which “bipolar families,” compared with families without a serious mental illness, incurred much higher medical costs, visited physicians more often, had more hospital stays, and spent more money on prescription­ drugs.
Mary Lou Chatterton, PharmD, Xiongkan Ke, MS, Barbara Edelman Lewis, PhD, MHA, Krithika Rajagopalan, PhD, and Arthur Lazarus, MD, MBA

Case Report

Aripiprazole (Abilify) and Tardive Dyskinesia

Second-generation atypical antipsychotic drugs carry a lower risk of extra­pyramidal symptoms and tardive dyskinesia compared with conventional agents, but they are not without their dangers. The case report of a 46-year-old patient demonstrates the point that the newer agents should be used according to their FDA-approved indications, when possible, and that patients using aripiprazole, an “atypical atypical” agent, need to be carefully monitored.
Thomas Schwartz, MD, and Shafi Raza, MD

Advances in Vaccine Technology and Their Impact On Managed Care

Although the “vaccine revolution” has resulted in products that can prevent illness­ and reduce costs of disease, the authors raise several concerns: who will pay for these improvements, how these advances will alter treatment, how cost and efficacy will be balanced, and how to choose the right product.
Jonathan A. McCullers, MD, and Jeffrey D. Dunn, PharmD, MBA

Meeting Highlights

American Heart Association, 2007 Scientific Sessions

Presentations cover a number of clinical trials of cardiac agents, including clopidogrel­ versus prasugrel; an investigative thrombin receptor antagonist; a niacin/simvastatin­ combination; warfarin dosing versus genotype-guided dosing; clopidogrel eptifibatide, and bivalirudin; and eptifibatide versus abciximab.
Walter Alexander

Pharmaceutical Approval Update

Topics include nilotinib (Tasigna Capsules) for the treatment of chronic mye­logenous leukemia (CML), raltegravir (Isentress) for patients with HIV-1 infection, and ixabepilone (Ixempra), combined with capecitabine (Xeloda), for use in metastatic or locally advanced breast cancer.
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial

Better

David Nash, MD, MBA, reviews Better: A Surgeon’s Notes on Performanc­e, a book in which Dr. Atul Gawande asserts that our health care system won’t im­prove­ until we rethink our everyday practices.
David Nash, MD, MBA

Medication Errors

Safety and Patient-Controlled Analgesia Part 2: How to Prevent Errors

In Part 2 of a two-part series, Matthew Grissinger, RPh, FASCP, details the steps needed for safely prescribing and dispensing patient-controlled­ analgesia (PCA).
Matthew Grissinger, RPh, FASCP

Prescription: Washington

FDA Considers New Avenue for Pharmacist Reimbursement

Stephen Barlas discusses how consumers might have access to a number of “behind-the-counter” drugs only after they are counseled by a pharmacist.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

From cephipeme to valsartan, P&T presents the latest information about FDA approvals, new indications, recalls, and industry updates.

Drug Forecast

Dalbavancin (Zeven), a Novel Glycopeptide for Resistant Gram-Positive Organisms

Drs. Colabella and Chagan review dalbavancin (Zeven), a glycopeptide for resistant gram-positive organisms.
Jennifer Colabella, PharmD, and Larisa Chagan, PharmD, BCPS